Know Cancer

or
forgot password

A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer


Phase 2
18 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer


Inclusion Criteria:



- Men with histologically proven prostatic carcinoma, stage cT2, N0, M0, receiving
neoadjuvant bicalutamide plus conformal radiotherapy in study 9907, who have
previously participated in the prostate cancer hypoxia project

- informed consent

Exclusion Criteria:

- Coagulopathy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours, and to correlate with changes in PSA, hemoglobin level, and prostate volume.

Principal Investigator

Michael Milosevic, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Princess Margaret Hospital, Canada

Authority:

Canada: Ethics Review Committee

Study ID:

UHN REB 00-0430-C

NCT ID:

NCT00188708

Start Date:

April 2001

Completion Date:

Related Keywords:

  • Prostatic Neoplasms
  • Neoplasms
  • Prostatic Neoplasms
  • Anoxia

Name

Location